,68,69 Currently, Fgf21 analogs pegbelfermin (BMS-986036) and Fgf19 analog aldafermin (NGM282) were found to present significant therapeutic effects in NASH patients (NCT03486899 and NCT03912532).70 The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.